PP2A activator FTY720 has shown protective capability. Current trend toward phosphatase activators in cancer therapeutics may provide opportunity to examine cardiac effects. Limitations: Transgenic overexpression of phosphatase subunits has been associated with cardiac disease. The gene discussed is PTPA; the disease is heart disorder.